Purple Biotech shares soared 92% after the company achieved a key manufacturing milestone for its experimental cancer drug IM1240, a tri-specific antibody targeting the 5T4 tumor antigen. The biotech plans to file for FDA approval in 2026 to begin human trials, marking major progress for its CAPTN-3 platform.